NCT05363800Active, not recruitingPhase 1
Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
Source: ClinicalTrials.gov · Last updated 5 Jun 2026
Brief summary (registry, in English)
This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of HRS-3738 in patients with recurrent and refractory Non-Hodgkin's lymphoma and multiple myeloma.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 74 (actual)
- First submitted
- 25 Apr 2022
- Start date
- 17 Jun 2022
- Primary completion date
- 30 Dec 2026
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Diseases
- Multiple myeloma
- NCT number
- NCT05363800
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 74
- From 17 Jun 2022 to the primary completion date, 30 Dec 2026
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment of other investigational products.
- Major surgical therapy within 28 days prior to the date of signature of informed consent form, or expected major surgery during the study.
Other illness
- Known history of hypersensitivity to any components of HRS-3738.
Lab values
- Corrected serum calcium\>3.4mmol/L(13.5mg/dl).
Other
- Amyloidosis, plasma cell leukemia.
- Presence of metastasis to central nervous system.
- Other factors that may affect the study results or lead to forced termination of the study early as judged by investigators.
Who the study is looking for
- Active multiple myeloma in accordance with IMWG criteria，or histopathologically and immunohistochemically confirmed non-Hodgkin's lymphoma in accordance with the 2016 WHO Classification of lymphoid neoplasias.
- Recurred or did not alleviate after the previous treatment.
- Have at least one measurable lesion.
- With a life expectancy of ≥3 months.
- Male or female ≥ 18 years old.
- ECOG performance status of 0-1.
- Subjects must voluntarily agree to participate in the trial and sign a written informed consent form.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhejiang University School of Medicine The First Affiliated Hospital Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
| Sheng Jing Hospital of China Medical University Coordinator of this site? Confirm its status | Shengyang | China | Unknown status |
| Henan Cancer Hospital Coordinator of this site? Confirm its status | Zhengzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.